Latest News

Market context and recent trading action YD Bio (YDES) has quietly turned heads after a sharp move over the past month, with the stock up roughly 43% even as its past 3 months performance remains deeply negative. See our latest analysis for YD Bio. That recent 1 month share price return of about 43% has only partially repaired earlier damage, leaving the 3 month share price return sharply negative even as the year to date share price return turns modestly positive. This suggests momentum is...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Key Insights Institutions' substantial holdings in Contact Energy implies that they have significant influence over the...

With its stock down 16% over the past three months, it is easy to disregard Objective (ASX:OCL). But if you pay close...

Genasys (GNSS) just posted its FY 2025 third quarter numbers, with revenue of about $9.9 million and a basic EPS loss of roughly $0.14, setting the stage for another closely watched update on its path toward profitability. The company has seen quarterly revenue move from about $5.7 million in Q2 FY 2024 to $6.7 million in Q4 FY 2024 and then to the current $9.9 million print in Q3 FY 2025. Over the same stretch, basic EPS has ranged from a $0.26 loss to the latest $0.14 loss, keeping margins...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...

Key Insights The considerable ownership by private companies in Cohance Lifesciences indicates that they collectively...

Hazer Group Limited ( ASX:HZR ) shareholders should be happy to see the share price up 12% in the last quarter. But...

SGH Limited ( ASX:SGH ) received a lot of attention from a substantial price movement on the ASX over the last few...

Focus Lighting and Fixtures Limited's ( NSE:FOCUS ) price-to-sales (or "P/S") ratio of 3.1x may not look like an...

Castrol India (NSE:CASTROLIND) has had a rough three months with its share price down 6.6%. But if you pay close...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 26x, you may consider The...

With a price-to-earnings (or "P/E") ratio of 33.4x Matrimony.com Limited ( NSE:MATRIMONY ) may be sending bearish...

What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...

United Polyfab Gujarat Limited ( NSE:UNITEDPOLY ) shareholders won't be pleased to see that the share price has had a...

Avenue Supermarts Limited ( NSE:DMART ) shareholders might be concerned after seeing the share price drop 17% in the...

Aarti Drugs Limited ( NSE:AARTIDRUGS ) shareholders that were waiting for something to happen have been dealt a blow...

HBL Engineering Limited ( NSE:HBLENGINE ) shareholders won't be pleased to see that the share price has had a very...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

MedinCell (ENXTPA:MEDCL) has been in focus after partner Teva filed a New Drug Application with the U.S. FDA for its olanzapine long acting injectable, which is built on MedinCell’s BEPO technology. See our latest analysis for MedinCell. The latest regulatory milestone appears to have reignited interest in MedinCell, with the 1 day share price return of 3.85 percent and a 90 day share price return of 41.39 percent contributing to a robust 1 year total shareholder return of 77.19 percent. This...